AI TECHNOLOGY

By combining AI technology and accumulated novel drug development know-how, we are committed to dramatically reduce the research period and cost by maximizing the efficiency of the drug development process. In order to treat various diseases, we develop our own AI drug research pipeline, and we will lead the novel drug development paradigm through various cooperative relationships.

mRNA/Nanoparticle

MOGAM has exceptional history of experience specializing in developing protein-based therapeutics, such as PEGylated G-CSF, coagulation factors, and monoclonal antibodies. Moving towards the next generation of therapeutics, we are now focusing on mRNA therapeutics using artificial intelligence. Based on our existing competencies, we have been researching mRNA components and nanoparticles (NPs) and increasing our competitiveness through open innovation.

Protein Engineering

We want to design novel drugs by predicting protein characteristics through protein sequence and structure optimization using AI.